Aligos Therapeutics, Inc. Accumulated Other Comprehensive Income
Aligos Therapeutics, Inc. (ALGS) had Accumulated Other Comprehensive Income of $437.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $437.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $438.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $468.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $455.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $437.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $438.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $468.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $455.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $420.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $447.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $451.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $577.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $494.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | $476.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $545.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $497.00K 10-Q · filed 2023-11-02 |
| 2023-06-30 | $497.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $499.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $401.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | $159.00K 10-Q · filed 2022-11-02 |
| 2022-06-30 | $50.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $204.00K 10-Q · filed 2022-05-04 |
| 2021-12-31 | $452.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | -$250.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$251.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$227.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | -$188.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $32.00K 10-Q · filed 2020-11-25 |
| 2019-12-31 | -$115.00K 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |